- Home
- ESLA vs LTRN Comparison
ESLA vs LTRN Comparison
Compare ESLA & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESLA
- LTRN
- Stock Information
- Founded
- ESLA 2021
- LTRN 2013
- Country
- ESLA United States
- LTRN United States
- Employees
- ESLA N/A
- LTRN N/A
- Industry
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- LTRN Biotechnology: Pharmaceutical Preparations
- Sector
- ESLA Health Care
- LTRN Health Care
- Exchange
- ESLA Nasdaq
- LTRN Nasdaq
- Market Cap
- ESLA 32.1M
- LTRN 38.0M
- IPO Year
- ESLA N/A
- LTRN 2020
- Fundamental
- Price
- ESLA $1.02
- LTRN $3.73
- Analyst Decision
- ESLA Strong Buy
- LTRN Buy
- Analyst Count
- ESLA 1
- LTRN 2
- Target Price
- ESLA $16.00
- LTRN $25.00
- AVG Volume (30 Days)
- ESLA 79.4K
- LTRN 43.8K
- Earning Date
- ESLA 05-14-2025
- LTRN 05-08-2025
- Dividend Yield
- ESLA N/A
- LTRN N/A
- EPS Growth
- ESLA N/A
- LTRN N/A
- EPS
- ESLA N/A
- LTRN N/A
- Revenue
- ESLA N/A
- LTRN N/A
- Revenue This Year
- ESLA N/A
- LTRN N/A
- Revenue Next Year
- ESLA N/A
- LTRN N/A
- P/E Ratio
- ESLA N/A
- LTRN N/A
- Revenue Growth
- ESLA N/A
- LTRN N/A
- 52 Week Low
- ESLA $0.63
- LTRN $2.55
- 52 Week High
- ESLA $3.23
- LTRN $7.21
- Technical
- Relative Strength Index (RSI)
- ESLA 58.11
- LTRN 55.76
- Support Level
- ESLA $0.78
- LTRN $3.00
- Resistance Level
- ESLA $0.87
- LTRN $3.71
- Average True Range (ATR)
- ESLA 0.11
- LTRN 0.36
- MACD
- ESLA 0.02
- LTRN 0.08
- Stochastic Oscillator
- ESLA 92.80
- LTRN 85.51
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.